6533b820fe1ef96bd127a482
RESEARCH PRODUCT
Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms
Otto BenkertHermann WetzelA. HillertGerd Gründersubject
Agonistmedicine.medical_specialtyPsychosismedicine.drug_classDopamine AgentsGastroenterologyReceptors Dopaminechemistry.chemical_compoundRoxindoleInternal medicinemental disordersSchizophrenic PsychologymedicineHumansProspective StudiesScale for the Assessment of Negative SymptomsPsychiatric Status Rating ScalesSchizophrenia ParanoidDose-Response Relationship Drugbusiness.industrymedicine.diseaseHospitalizationPsychiatry and Mental healthTreatment OutcomeEndocrinologychemistrySchizophreniaDopamine receptorSchizophreniaAutoreceptorSchizophrenic Psychologybusinessdescription
Twenty schizophrenic inpatients with either predominantly positive or predominantly negative symptoms were treated with the dopamine autoreceptor agonist roxindole in prospective open clinical trials. There was no antipsychotic effect in the subgroup with positive symptoms, whereas the subgroup with negative symptoms, especially those with the residual type of schizophrenia, showed a moderate but significant 20% reduction in total scores on the Scale for the Assessment of Negative Symptoms.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1994-10-01 | American Journal of Psychiatry |